Durata Therapeutics To Present At Bank Of America Merrill Lynch 2013 Healthcare Conference

CHICAGO, May 7, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 14, 2013 at 10:40 AM PT at the Encore at the Wynn Las Vegas.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria.

Forward-looking statements

Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.
CONTACT: Allison Wey         Durata Therapeutics, Inc.         Vice President, Investor Relations and Public Affairs         (312) 219-7017         awey@duratatherapeutics.com

Durata Therapeutics, Inc. Logo

If you liked this article you might like

Why Durata Therapeutics (DRTX) Stock Hit a One-Year High Today

Why Durata Therapeutics (DRTX) Stock Hit a One-Year High Today

5 Stocks Moving on Unusual Volume

5 Stocks Moving on Unusual Volume

Emerging 'Superbugs' -- and Why Investors Should Care

Emerging 'Superbugs' -- and Why Investors Should Care

2014 FDA Drug Approval Decision Calendar

2014 FDA Drug Approval Decision Calendar

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan